Mind the gap in kidney care: translating what we know into what we do

Valerie A Luyckx1,2,3, Katherine R Tuttle3,4,5, Dina Abdellatif6

  • 1Department of Public and Global Health, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland.

Insights

It takes too long to implement new kidney disease treatments. Early diagnosis and treatment are crucial but hindered by many barriers, requiring immediate action to improve global kidney health.

Area of Science:

  • Nephrology
  • Public Health
  • Health Services Research

Background:

  • A significant delay exists in translating kidney disease research into clinical practice.
  • Effective treatments are available to prevent or slow kidney disease, yet implementation lags.
  • Many individuals with risk factors like hypertension and diabetes, or kidney disease itself, remain undiagnosed or undertreated.

Purpose of the Study:

  • To highlight the critical need to accelerate the adoption of evidence-based kidney disease treatments.
  • To identify barriers preventing timely diagnosis and management of kidney disease.
  • To advocate for maximizing early diagnosis and treatment opportunities, particularly at the primary care level.

Main Methods:

  • This study is a review and synthesis of current knowledge on kidney disease treatment implementation.
  • It analyzes systemic barriers across patient, clinician, health system, and societal levels.
  • The focus is on identifying gaps between established guidelines and clinical practice.

Main Results:

  • A substantial gap persists between kidney disease knowledge and its application in patient care.
  • Diagnosis rates for hypertension, diabetes, and kidney disease are low globally.
  • Even diagnosed patients often do not receive optimal kidney disease management.

Conclusions:

  • Urgent action is needed to reduce the 17-year average delay in implementing kidney disease treatments.
  • Addressing multifaceted barriers is essential for improving early diagnosis and appropriate management.
  • Sustainable solutions must be developed and implemented to preserve and enhance global kidney health.

Related Concept Videos

Kidney Structure01:45

Kidney Structure

The kidneys are two large bean-shaped organs located in the upper abdomen. They filter the blood several times a day to remove toxins and rebalance water and electrolytes of the circulatory system via the renal veins. The kidneys receive blood directly from the heart via the renal arteries. These arteries enter the kidney at the hilum, the concave surface of the bean, where they branch and divide into smaller vessels and capillaries.
68.7K
Dialysis01:27

Dialysis

Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
260
Internal Anatomy of the Kidney01:12

Internal Anatomy of the Kidney

The kidneys are essential organs in the human body, performing a myriad of tasks that maintain homeostasis and overall health.
Anatomical Position and Dimensions
The kidneys are retroperitoneal organs positioned against the posterior abdominal wall on either side of the spine, roughly between the twelfth thoracic and third lumbar vertebrae. Each kidney is typically 10-12 cm long, 5-6 cm wide, and 3-4 cm thick, weighing about 150 grams.
Renal Cortex
The outermost region of the kidney is the...
1.3K
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
117